Perioperative pembrolizumab enhances survival rates in advanced head and neck cancer, paving the way for earlier ...

Pembrolizumab combined with chemoradiation shows promising long-term efficacy and safety in treating advanced non-small cell ...

Combination cohort initiated following successful review of monotherapy cohortOver 100 participants dosed to-date in ...

In this video, Susana M. Campos, MD, MPH, discusses results from the final analysis of the phase 3 A18 study in advanced cervical cancer, presented at ASCO Annual Meeting.The ...

Keytruda (pembrolizumab) is approved for head and neck squamous cell carcinoma as a perioperative treatment regimen.

The vaccine is being developed in partnership with Cleveland Clinic and the phase one trial is fully funded by a grant from ...

Dr Heather McArthur describes how ASCO 2025 showcased new standards of care in triple-negative and HER2-positive settings.

Neoadjuvant cobolimab and dostarlimab followed by surgery and adjuvant dostarlimab may confer benefits over perioperative pembrolizumab in patients with high-risk, resectable melanoma.

In this video, Megan Kruse, MD, breast medical oncologist at Cleveland Clinic, discusses primary results from ASCENT-04 ...

Trial in Recurrent Head and Neck Cancer ATLANTA, GA - June 24, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and ...

Technological advances in the design and delivery of mRNA have catalysed the rapid development of mRNA COVID-19 vaccines by ...